- US-listed companies
- Aligos Therapeutics, Inc.
- Income statement
Aligos Therapeutics, Inc.【ALGS】Income statement
Market cap
$6.18M
P/E ratio
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | 6 | 4 |
| Revenue growth (%) | - | - | - | - | |
| Research & development | 80 | 104 | 85 | 73 | 70 |
| Operating margin (%) | - | - | - | ||
| Operating expenses | 98 | 133 | 111 | 104 | 93 |
| Operating income | -98 | -128 | -98 | -88 | -89 |
| Income before tax | -108 | -128 | -96 | -87 | -131 |
| Pretax margin (%) | - | - | - | -1,403.4 | -3,624.5 |
| Provision for income taxes | 0 | 0 | 0 | 1 | 0 |
| Effective tax rate (%) | |||||
| Net income | -109 | -128 | -96 | -88 | -131 |
| Net income margin (%) | - | - | - | ||
| Earnings per share | - | - | - | -1.36 | -20.94 |
| Diluted EPS | - | - | - | -1.36 | -20.94 |